Suppr超能文献

高尿酸血症、痛风、降尿酸治疗与骨关节炎之间的关联:一项系统评价与荟萃分析方案

Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis.

作者信息

Zhu Junyu, Wang Yilun, Chen Yuhao, Li Xiaoxiao, Yang Zidan, Li Hui

机构信息

Department of Orthopaedics, Xiangya Hospital, Central South University.

Hunan Key Laboratory of Joint Degeneration and Injury.

出版信息

Medicine (Baltimore). 2020 Aug 14;99(33):e21610. doi: 10.1097/MD.0000000000021610.

Abstract

INTRODUCTION

Osteoarthritis (OA), a chronic and degenerative joint disease characterized by articular cartilage degeneration, sclerosis of subchondral bone, and osteophyte formation, is deemed a leading cause of activity limitation and disability among the elderly people. Serum uric acid (UA) is a terminal metabolite of purine compound, while hyperuricemia (HU) and UA crystals are recognized causes of gout. Several studies have investigated the correlations between HU, gout and OA, but the findings are inconclusive. We are also concerned whether the urate lowering therapy (ULT) can become a potential treatment for OA and intend to undertake this meta-analysis to clarify the related hypotheses.

METHODS

Systematic literature search will be conducted on PubMed, Embase, and Web of Science to identify relevant studies up to February 2020 using appropriate search strategies. All citations and abstracts retrieved from literature search will be assessed by two reviewers independently. The Newcastle-Ottawa Scale or the Cochrane risk of bias assessment tool will be used as appropriate to assess the quality and the risk of bias of the included studies. The heterogeneity and the publication bias of the studies will be investigated accordingly.

RESULTS

We propose to undertake this meta-analysis as a feasible approach to clarify the associations between HU, gout or ULT, and OA.

DISCUSSIONS

This meta-analysis will help to strengthen our knowledge of the pathogenesis of OA and promote the development of preventive or treatment strategies.

REGISTRATION

PROSPERO registration number CRD42020168769.

摘要

引言

骨关节炎(OA)是一种慢性退行性关节疾病,其特征为关节软骨退变、软骨下骨硬化和骨赘形成,被认为是老年人活动受限和残疾的主要原因。血清尿酸(UA)是嘌呤化合物的终末代谢产物,而高尿酸血症(HU)和尿酸晶体是痛风的公认病因。多项研究探讨了HU、痛风与OA之间的相关性,但结果尚无定论。我们还关注降尿酸治疗(ULT)是否能成为OA的潜在治疗方法,并打算进行这项荟萃分析以阐明相关假设。

方法

将在PubMed、Embase和Web of Science上进行系统的文献检索,使用适当的检索策略识别截至2020年2月的相关研究。从文献检索中检索到的所有引文和摘要将由两名审稿人独立评估。将酌情使用纽卡斯尔-渥太华量表或Cochrane偏倚风险评估工具来评估纳入研究的质量和偏倚风险。将相应地调查研究的异质性和发表偏倚。

结果

我们建议进行这项荟萃分析,作为一种可行的方法来阐明HU、痛风或ULT与OA之间的关联。

讨论

这项荟萃分析将有助于加强我们对OA发病机制的认识,并促进预防或治疗策略的发展。

注册

PROSPERO注册号CRD42020168769。

相似文献

3
Cardiovascular Safety of Urate Lowering Therapies.
Curr Rheumatol Rep. 2019 Jul 24;21(9):48. doi: 10.1007/s11926-019-0843-8.
4
Effect of urate-lowering therapy on all-cause and CVD-specific mortality in gout and hyperuricemia: a meta-analysis.
Z Rheumatol. 2024 Dec;83(Suppl 3):338-344. doi: 10.1007/s00393-024-01600-0. Epub 2024 Dec 5.
5
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
Int J Rheum Dis. 2018 Apr;21(4):772-787. doi: 10.1111/1756-185X.13266. Epub 2018 Jan 24.
6
Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
J Gen Intern Med. 2018 Mar;33(3):358-366. doi: 10.1007/s11606-017-4233-5. Epub 2017 Dec 4.
9
Uric acid en route to gout.
Adv Clin Chem. 2023;116:209-275. doi: 10.1016/bs.acc.2023.05.003. Epub 2023 Jun 7.

引用本文的文献

1
The impact of uric acid on musculoskeletal diseases: clinical associations and underlying mechanisms.
Front Endocrinol (Lausanne). 2025 Feb 4;16:1515176. doi: 10.3389/fendo.2025.1515176. eCollection 2025.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验